|
Therapy Area
Protease inhibitor for the treatment of patients with HIV.
|
|
In phase
Preclinical optimization phase. |
Competitive edge
HIV protease inhibitor with highly potent antiviral effect in a cell-based assay has been identified. |
Project data
- Collaboration with Tibotec Pharmaceuticals Ltd. since 30 June 2006
- Inhibitor with very potent activity against wild-type HIV and resistant virus.
|
Main products 2006
Kaletra Abbott
Reyataz Bristol-Myers Sqibb
Crixivan Merck
Viracept Roche
Norvir Abbott
|
|
Updated: 28/03/2007
|
